These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28566882)

  • 1. Platelets in liver disease, cancer and regeneration.
    Kurokawa T; Ohkohchi N
    World J Gastroenterol; 2017 May; 23(18):3228-3239. PubMed ID: 28566882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel functions of platelets in the liver.
    Kurokawa T; Zheng YW; Ohkohchi N
    J Gastroenterol Hepatol; 2016 Apr; 31(4):745-51. PubMed ID: 26632220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable Liver Function during Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease.
    Kurokawa T; Murata S; Ohkohchi N
    Tohoku J Exp Med; 2016 Dec; 240(4):277-279. PubMed ID: 27928110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis.
    Murata S; Maruyama T; Nowatari T; Takahashi K; Ohkohchi N
    Int J Mol Sci; 2014 Mar; 15(4):5412-25. PubMed ID: 24686514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C.
    Dusheiko G
    Clin Liver Dis; 2009 Aug; 13(3):487-501. PubMed ID: 19628164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure.
    Giannini EG; Peck-Radosavljevic M
    Semin Thromb Hemost; 2015 Jul; 41(5):455-61. PubMed ID: 26049067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
    Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
    Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
    Aguilar C
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of platelets in chronic liver disease and acute liver injury.
    Nowatari T; Murata S; Fukunaga K; Ohkohchi N
    Hepatol Res; 2014 Feb; 44(2):165-72. PubMed ID: 23841688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombocytopenia after liver transplantation: Should we care?
    Takahashi K; Nagai S; Safwan M; Liang C; Ohkohchi N
    World J Gastroenterol; 2018 Apr; 24(13):1386-1397. PubMed ID: 29632420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.
    Farrell C; Hayes SC; Wire M; Zhang J
    Br J Clin Pharmacol; 2014 Mar; 77(3):532-44. PubMed ID: 24117976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentration.
    Panasiuk A; Prokopowicz D; Zak J; Panasiuk B
    Hepatogastroenterology; 2004; 51(58):1124-8. PubMed ID: 15239259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapy for liver regeneration by increasing the number of platelets.
    Takahashi K; Murata S; Ohkohchi N
    Surg Today; 2013 Oct; 43(10):1081-7. PubMed ID: 23180116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombocytopenia associated with chronic liver disease.
    Afdhal N; McHutchison J; Brown R; Jacobson I; Manns M; Poordad F; Weksler B; Esteban R
    J Hepatol; 2008 Jun; 48(6):1000-7. PubMed ID: 18433919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
    Serebruany VL; Eisert C; Sabaeva E; Makarov L
    Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia.
    Aref S; Mabed M; Selim T; Goda T; Khafagy N
    Hematology; 2004; 9(5-6):351-6. PubMed ID: 15763973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
    Olson SR; Koprowski S; Hum J; McCarty OJT; DeLoughery TG; Shatzel JJ
    Platelets; 2019; 30(6):796-798. PubMed ID: 30422039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.